Goldman Sachs raises CBOE Holdings stock price target on cost cuts

Cboe reported Q1 2026 EPS of $3.70, beating the $3.25 consensus by 13.85%, with revenue of $729 million versus $693.75 million expected. Management raised 2026 organic revenue guidance to low double-digit to mid-teens growth from mid-single digits and lowered expense guidance to $838 million-$853 million from $864 million-$879 million. Goldman Sachs lifted its price target to $282 from $265 despite keeping a Sell rating, while Barclays raised its target to $382 from $351 and stayed Overweight.

Analysis

The market is treating CBOE’s restructuring as a clean earnings unlock, but the second-order effect is that management is effectively shrinking the low-conviction parts of the franchise while concentrating capital into the most defensible data and derivatives monetization engines. That tends to improve quality of earnings, but it also reduces optionality from non-core geographies, so the upside case is more about multiple support from margin durability than outright top-line acceleration. In other words, the rerating path is likely to be slower than the recent guidance revision suggests because investors will want proof that the lost revenue is truly replaced by higher-retention, higher-multiple revenue streams.

The main risk is timing mismatch: expense savings arrive quickly, while revenue leakage from divestitures and workforce cuts can show up immediately in reported growth optics. That creates a window over the next 1-2 quarters where headline guidance can look better but consensus may hesitate to chase the stock unless trading volumes stay elevated and Data Vantage reacceleration is visible in monthly commentary. If markets normalize and volumes soften, the leverage embedded in the cost takeout story becomes less powerful than the current sell-side enthusiasm implies.

Goldman’s raise while keeping a Sell is the important tell: the firm is acknowledging estimate revision momentum, not endorsing valuation. With the stock near highs, the stock is increasingly a “prove-it” story, and the consensus may be underappreciating how much good news is already embedded in the multiple. The contrarian read is that the restructuring could be enough to justify the earnings path, but not enough to justify paying peak-cycle scarcity value unless management can show sustained Data Vantage growth and continued share gains in listed derivatives through year-end.

Key Decisions for Investors

• Short CBOE on strength or sell call spreads 1-3 months out; the risk/reward favors a pause if the post-guidance multiple already discounts 2027 upside and revenue conversion lags the cost takeout.
• If holding a bearish view, express it as a pair: short CBOE vs long BATS/ICE over 3-6 months, targeting relative multiple compression if CBOE’s valuation remains stretched while peers offer cleaner growth/cash-flow visibility.
• For long-only portfolios, wait for a pullback before adding; entry below the recent high provides better asymmetry because the next catalyst is likely execution proof, not a fresh re-rating headline.
• Monitor the next 1-2 quarterly updates in Data Vantage and transaction volumes; if organic growth decelerates or volume trends normalize, expect the market to cut the incremental upside embedded in 2027 estimates.
• If you want upside exposure, use limited-risk calls only after confirmation of post-restructuring margin stability; the trade is a tactical momentum expression, not a high-conviction multi-quarter long at current valuation.